P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients.

Sajjan, U S; Tran, L T; Sole, N; Rovaldi, C; Akiyama, A; Friden, P M; Forstner, J F; Rothstein, D M

Sajjan, U S; Tran, L T; Sole, N; Rovaldi, C; Akiyama, A; Friden, P M; Forstner, J F; Rothstein, D M.

Affiliation

Sajjan US; The Hospital for Sick Children, Toronto, Ontario, Canada.

Antimicrob Agents Chemother ; 45(12): 3437-44, 2001 Dec.

Article in En | MEDLINE | ID: mdl-11709321

Subject(s)

Anti-Bacterial Agents/pharmacology; Cystic Fibrosis/microbiology; Pseudomonas aeruginosa/drug effects; Saralasin/pharmacology; Sputum/microbiology; Cystic Fibrosis/complications; Cystic Fibrosis/metabolism; Deoxyribonucleases/pharmacology; Humans; Isomerism; Microbial Sensitivity Tests; Pseudomonas Infections/complications; Pseudomonas Infections/microbiology; Saralasin/chemistry; Sputum/chemistry; Stereoisomerism

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pseudomonas aeruginosa / Sputum / Saralasin / Cystic Fibrosis / Anti-Bacterial Agents Limits: Humans Language: En Journal: Antimicrob Agents Chemother Year: 2001 Document type: Article Affiliation country: Canada Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google